Analyst warns that GSK’s ‘strategic masterstroke’ with Ribena Plus could backfire
Despite shrewd use of an EU ‘immunity support’ health claim, GlaxoSmithKline’s (GSK’s) new Ribena Plus risks consumer confusion and cannibalisation of regular product sales, a beverage industry expert has warned.